Oxford Drug Design
The AI engine Fit Assessment
BetaInhibOx leverages advanced machine learning technologies and pattern discovery methods to expand therapeutic options, particularly in the development of novel antibiotics.
Blurb
HQ Location
Founded
Employees
Total funding raised
Funding Status
- Drug Discovery Optimization
- Drug Repurposing
Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods.
We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes.
Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action.